Baxalta Incorporated is a biopharmaceutical company. The Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions. The Company also focuses on disease areas, including oncology, as well as technology platforms, including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas, including hemophilia, immunology and oncology. The Company's products include ADVATE, RECOMBINATE, HEMOFIL M, Immunate, Immunine, PROTHROMPLEX TOTAL, RIXUBIS, FACTOR VII NF, BEBULIN, FEIBA, OBIZUR, GAMMAGARD LIQUID, GAMMAGARD S/D, Subcuvia, HYQVIA, FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP, CEPROTIN and ANTITHROMBIN III IMMUNO.